A groundbreaking cancer detection system utilizing artificial intelligence (AI) technology is set to significantly improve cancer survival rates, as unveiled by British GP Dr Bea Bakshi at the American Society of Clinical Oncology (ASCO) conference in Chicago.
Dr Bakshi, the co-founder and CEO of C the Signs, a cancer detection system in the UK, presented findings from a groundbreaking study that showcased how AI technology can revolutionize early cancer diagnosis and ultimately save lives.
The study, which involved 118,677 patients, demonstrated the effectiveness of the highly sensitive C the Signs system in real-life scenarios. It successfully detected cancer in patients, ensuring they were not missed during risk assessment. The system also demonstrated accuracy in identifying the origin of the cancer, assisting doctors in appropriately directing patients to the right treatment departments.
“The results of our investigations to assess the accuracy of using AI technology in a real-world setting are extremely exciting,” stated Dr Bakshi. She further emphasized that as the system continues to evolve and be utilized more extensively, it will become even more sensitive, accurate, and effective. Dr Bakshi highlighted additional unpublished data that indicates even better outcomes with the evolving system, which will be disclosed soon.
With over 1,000 primary care practices and 15,000 healthcare professionals in the UK already employing the C the Signs platform, Dr Bakshi and her team have now expanded their efforts to the United States, establishing partnerships with US health systems.
The presentation of this study coincides with the launch of the CancerX initiative, a part of the Cancer Moonshot program led by the White House and President Biden. The goal of CancerX, a public and private partnership, is to reduce cancer mortality. C the Signs is among the founding members of CancerX and believes that its AI technology will play a pivotal role in achieving the initiative’s ambitious objective of reducing cancer deaths by 50% by 2040.
Dr Bakshi expressed her honor in being a founding member of the program and expressed confidence that C the Signs, along with AI technology and advancements in cancer prediction and detection, will contribute significantly to reaching this goal.
The CancerX partnership aims to establish best practices, build capacity, and demonstrate the impact of innovation in the fight against cancer. It brings together a diverse and inclusive community of pioneers committed to advancing the goals of the Cancer Moonshot program.
Through this collaborative effort, the CancerX initiative seeks to harness the potential of digital innovation, facilitate knowledge sharing, and accelerate the development and equitable deployment of innovative solutions in the battle against cancer.
Dr Bakshi’s presentation at the ASCO conference marks a milestone in the journey towards utilizing AI technology to transform cancer diagnosis and treatment. The findings offer hope for improved cancer survival rates and signify a significant step forward in the fight against this devastating disease. More details about the study can be found here: https://meetings.asco.org/abstracts-presentations/219520.
